Eric J. Bycer

Array ( [id] => 16282638 [patent_doc_number] => 20200276240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => NUCLEIC ACID MOLECULES ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/844759 [patent_app_country] => US [patent_app_date] => 2020-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50554 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 957 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16844759 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18153118 [patent_doc_number] => 11566079 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-31 [patent_title] => Subcutaneous formulations of anti-CD38 antibodies and their uses [patent_app_type] => utility [patent_app_number] => 16/840153 [patent_app_country] => US [patent_app_date] => 2020-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23339 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16840153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16908996 [patent_doc_number] => 11041023 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-22 [patent_title] => Chimeric antigen receptors for phagocytosis [patent_app_type] => utility [patent_app_number] => 16/821551 [patent_app_country] => US [patent_app_date] => 2020-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 26 [patent_no_of_words] => 32026 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16821551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16312377 [patent_doc_number] => 20200291115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING DISEASES [patent_app_type] => utility [patent_app_number] => 16/819778 [patent_app_country] => US [patent_app_date] => 2020-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16819778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283795 [patent_doc_number] => 20200277397 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/813167 [patent_app_country] => US [patent_app_date] => 2020-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40775 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16813167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16482519 [patent_doc_number] => 20200376119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => METHODS OF TREATING CEA-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/787931 [patent_app_country] => US [patent_app_date] => 2020-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51360 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16787931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283798 [patent_doc_number] => 20200277400 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/784170 [patent_app_country] => US [patent_app_date] => 2020-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38745 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16784170 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18887752 [patent_doc_number] => 11866514 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-09 [patent_title] => Heterodimeric antibody Fc-containing proteins and methods for production thereof [patent_app_type] => utility [patent_app_number] => 16/777053 [patent_app_country] => US [patent_app_date] => 2020-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 64 [patent_figures_cnt] => 103 [patent_no_of_words] => 36961 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16777053 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238287 [patent_doc_number] => 20200255521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND ROR1 [patent_app_type] => utility [patent_app_number] => 16/773927 [patent_app_country] => US [patent_app_date] => 2020-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26660 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16773927 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15681309 [patent_doc_number] => 20200095318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => THERAPEUTIC CD47 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/703484 [patent_app_country] => US [patent_app_date] => 2019-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44086 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16703484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460313 [patent_doc_number] => 20220073618 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => HUMANIZED ANTI-HUMAN PD-L1 MONOCLONAL ANTIBODY AND PREPARATION METHOD THEREFOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/309252 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14381 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17309252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292221 [patent_doc_number] => 20210388060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => NOVEL METHOD FOR PRODUCING ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/289244 [patent_app_country] => US [patent_app_date] => 2019-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336343 [patent_doc_number] => 20220002674 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => T CELLS WITH SUICIDE SWITCH [patent_app_type] => utility [patent_app_number] => 17/288845 [patent_app_country] => US [patent_app_date] => 2019-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15980 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18733439 [patent_doc_number] => 11802162 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-31 [patent_title] => Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof [patent_app_type] => utility [patent_app_number] => 16/663583 [patent_app_country] => US [patent_app_date] => 2019-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 104 [patent_figures_cnt] => 147 [patent_no_of_words] => 80242 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16663583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17274503 [patent_doc_number] => 20210380701 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 17/287828 [patent_app_country] => US [patent_app_date] => 2019-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22964 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -60 [patent_words_short_claim] => 177 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15708785 [patent_doc_number] => 20200101158 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/659797 [patent_app_country] => US [patent_app_date] => 2019-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16659797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15768879 [patent_doc_number] => 20200115457 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-16 [patent_title] => CHIMERIC RECEPTORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/658480 [patent_app_country] => US [patent_app_date] => 2019-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26312 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16658480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15711201 [patent_doc_number] => 20200102366 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => CHIMERIC ANTIGEN RECEPTORS (CAR) AND METHODS FOR MAKING AND USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/600806 [patent_app_country] => US [patent_app_date] => 2019-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42325 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16600806 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238303 [patent_doc_number] => 20200255537 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => INTERNALIZING HUMAN MONOCLONAL ANTIBODIES TARGETING PROSTATE CANCER CELLS IN SITU [patent_app_type] => utility [patent_app_number] => 16/596684 [patent_app_country] => US [patent_app_date] => 2019-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24721 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16596684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15436257 [patent_doc_number] => 20200032312 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => SIALYLATED GLYCOPROTEINS [patent_app_type] => utility [patent_app_number] => 16/589634 [patent_app_country] => US [patent_app_date] => 2019-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17280 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16589634 [rel_patent_id] =>[rel_patent_doc_number] =>)